中国科技核心期刊
CN:31-1600/Q
ISSN:1004-0374
“健康与疾病的免疫”国际学术研讨会通知      关于有网站冒充本刊网站的声明
《生命科学》 2012, 24(3): 236-241
HSV-1溶瘤病毒的研究进展
朱 慧,郭景霞,马正海*
(新疆大学生命科学与技术学院,新疆生物资源基因工程重点实验室,乌鲁木齐 830046)
1004-0374(2012)03-0236-06
摘 要:1 型单纯疱疹病毒(Herpes simplex virus type 1, HSV-1) 感染效率高且易于通过基因工程改造,已广泛应用于肿瘤治疗研究和临床实验。溶瘤HSV-1 可通过基因工程改造或从HSV-1 自发突变株中筛选获得。研究证实溶瘤HSV-1 能够有效抑杀肿瘤细胞,可通过多种机制靶向肿瘤细胞,溶瘤HSV-1 与放化疗联合使用治疗肿瘤的研究也取得了理想的结果。目前,已有多个溶瘤HSV-1 进入临床试验。
关键词:1 型单纯疱疹病毒;溶瘤病毒;肿瘤治疗
中图分类号:R373 文献标志码:A
 
The research progress on HSV-1 oncolytic virus
ZHU Hui, GUO Jing-Xia, MA Zheng-Hai*
(Xinjiang Key Laboratory of Biological Resources and Genetic Engineering, the College of Life Science and Technology, Xinjiang University, Urumchi 830046, China)
Abstract: Herpes simplex virus type 1 (HSV-1) has been widely applied in the research of tumor therapy and preclinical trials because this virus is highly infectious and can be easily modified by genetic engineering. Oncolytic HSVs can be generated by genetic engineering technology or screened from spontaneous HSV-1 variants. It has been confirmed that oncolytic HSV-1 is a powerful tool to kill tumor cells, oncolytic HSVs can target tumor cells through several mechanisms, the research on combined therapy with oncolytic HSV-1 and radiotherapy (or chemotherapy) has also yielded encouraging results. At present, some oncolytic HSVs have reached clinical phase.
Key words: Herpes simplex virus type 1; oncolytic virus; tumor therapy
 
首页 | 刊物简介 | 编委会 | 投稿须知 | 广告业务 | 过刊浏览 | 联系我们
中国科学院上海生命科学信息中心《生命科学》编辑部
Copyright © 2012-2015 《生命科学》编辑部 All Rights Reserved.
沪ICP备05033115号-30
您是第2953417 位访问者,欢迎!